Integrated exposure –response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
ConclusionsThe relationships evidenced in this integrated E –R analysis support a favorable benefit-risk profile for lurbinectedin 3.2 mg/m2 q3wk.Trial registrationClinicaltrials.gov: NCT02454972; registered May 27, 2015.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lung Cancer | Small Cell Lung Cancer | Study | Thrombocytopenia